We also identified drugs that show higher specificity towards one or a few tumor types, e.g., ERK, MEK and BRAF inhibitors (AZ628, dabrafenib, PD0325901, PLX-4720, SB590885, SCH772984, and trametinib) for melanoma and colorectal cancer, ERBB/EGFR inhibitors (afatinib and sapitinib) for head-neck squamous cell carcinoma, and BCL2 inhibitors (ABT737, navitoclax and venetoclax) for low grade glioma and glioblastoma multiforme. This evidence concerns the gene EGFR and central nervous system cancer.